Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
Authors
Keywords
-
Journal
CIRCULATION
Volume 145, Issue 15, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-03-07
DOI
10.1161/cir.0000000000001056
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sensitivity and specificity of drug interaction databases to detect interactions with recently approved oral antineoplastics
- (2021) John B Bossaer et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies
- (2021) Andrew W. Swartz et al. ONCOLOGIST
- American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
- (2021) Gary H. Lyman et al. Blood Advances
- Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association
- (2021) Michael G. Fradley et al. CIRCULATION
- Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
- (2021) Susan F. Dent et al. Current Oncology Reports
- Chemotherapy‐associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies
- (2021) Justin A. Veeder et al. PHARMACOTHERAPY
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
- (2020) G. Curigliano et al. ANNALS OF ONCOLOGY
- The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology
- (2020) Olubadewa A. Fatunde et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
- (2020) Nicolas Palaskas et al. Journal of the American Heart Association
- Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
- (2020) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure
- (2020) Sarah Waliany et al. Annual Review of Pharmacology and Toxicology
- Direct oral anticoagulants in patients with hematologic malignancies
- (2020) Alessandra Serrao et al. HEMATOLOGICAL ONCOLOGY
- Drug-drug interactions affecting drug levels of direct oral anticoagulants in the real world: A systematic review
- (2020) Allen Li et al. THROMBOSIS RESEARCH
- Update on Guidelines for the Management of Cancer‐Associated Thrombosis
- (2020) Michael B. Streiff et al. ONCOLOGIST
- 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease
- (2020) Dharam J. Kumbhani et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Oral Anticancer Therapy: Management of Drug Interactions
- (2019) Britny G. Rogala et al. Journal of Oncology Practice
- Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib
- (2019) Viola Denzinger et al. THROMBOSIS AND HAEMOSTASIS
- Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
- (2019) Daniel Caldeira et al. PLoS One
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and targeted therapy combinations in metastatic breast cancer
- (2019) Francisco J Esteva et al. LANCET ONCOLOGY
- Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
- (2019) Giovanni Caocci et al. HEMATOLOGICAL ONCOLOGY
- Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
- (2019) C Ay et al. ANNALS OF ONCOLOGY
- Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges
- (2019) Julia Riedl et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma
- (2019) Ang Li et al. Journal of the National Comprehensive Cancer Network
- Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
- (2019) Ryan J. Sullivan et al. NATURE MEDICINE
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- (2019) Antoni Ribas et al. NATURE MEDICINE
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score
- (2019) Kristen M. Sanfilippo et al. AMERICAN JOURNAL OF HEMATOLOGY
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
- (2019) Nigel S. Key et al. JOURNAL OF CLINICAL ONCOLOGY
- Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint
- (2019) Bernhard Wernly et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies
- (2019) Christina W. Guo et al. EUROPEAN JOURNAL OF CANCER
- Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy
- (2019) Hanny Al-Samkari et al. Hematology-American Society of Hematology Education Program
- Cytochrome P450 Structure, Function and Clinical Significance: A Review
- (2018) Palrasu Manikandan et al. CURRENT DRUG TARGETS
- Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
- (2018) Andreas Schneeweiss et al. EUROPEAN JOURNAL OF CANCER
- Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice
- (2018) Robert Hermann et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms
- (2018) Joachim Alexandre et al. PHARMACOLOGY & THERAPEUTICS
- Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis
- (2018) Ang Li et al. THROMBOSIS RESEARCH
- Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Melanie Royce et al. JAMA Oncology
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations
- (2018) Dawn Swan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
- (2018) Elias Jabbour et al. Lancet Haematology
- The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival
- (2017) Taejong Song et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- (2017) Paul K. Whelton et al. HYPERTENSION
- Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies
- (2017) J. J. Shatzel et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Interplay between Pharmacokinetics and Pharmacodynamics
- (2017) Tracy L. Sandritter et al. PEDIATRICS IN REVIEW
- Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review
- (2017) Andreu Porta‐Sánchez et al. Journal of the American Heart Association
- Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary
- (2017) Saro H. Armenian et al. Journal of Oncology Practice
- Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion
- (2016) Massimo Breccia et al. ANNALS OF HEMATOLOGY
- Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy
- (2016) Caroline Gay et al. HEMATOLOGICAL ONCOLOGY
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thromboprophylaxis in multiple myeloma patients treated with lenalidomide – A systematic review
- (2016) Fatimah Al-Ani et al. THROMBOSIS RESEARCH
- Which QT Correction Formulae to Use for QT Monitoring?
- (2016) Bert Vandenberk et al. Journal of the American Heart Association
- Metabolism-related pharmacokinetic drug−drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations
- (2015) Yi Ling Teo et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologıa Interve
- (2015) Cezar Iliescu et al. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
- A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development
- (2015) Shingo Oda et al. Drug Metabolism and Pharmacokinetics
- 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
- (2015) Silvia G. Priori et al. EUROPEAN HEART JOURNAL
- L-asparaginase and venous thromboembolism in acute lymphocytic leukemia
- (2015) Gaurav Goyal et al. Future Oncology
- Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study
- (2015) Preetesh Jain et al. Lancet Haematology
- Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Outcomes in Women: Results From the Women's Health Initiative
- (2014) A. A. Bavry et al.
- Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)
- (2014) Evandro de Azambuja et al. JOURNAL OF CLINICAL ONCOLOGY
- Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
- (2014) Juan Carlos Plana et al. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
- QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review
- (2014) Marzia Locatelli et al. Targeted Oncology
- A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
- (2013) Dana E. Rathkopf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients
- (2013) James E. Tisdale et al.
- Interactions between oral antineoplastic agents and concomitant medication: a systematic review
- (2013) Esther Carcelero et al. Expert Opinion On Drug Safety
- Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors
- (2013) Alberto Farolfi et al. HEART
- Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
- (2013) Narayana I. Narasimhan et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The P-Glycoprotein Transport System and Cardiovascular Drugs
- (2013) Jeffrey D. Wessler et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension
- (2012) Hisham Aljadhey et al. BMC Cardiovascular Disorders
- Prevalence of QT Interval Prolongation in Patients Admitted to Cardiac Care Units and Frequency of Subsequent Administration of QT Interval-Prolonging Drugs
- (2012) James E. Tisdale et al. DRUG SAFETY
- Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
- (2012) E. J. A. Bowles et al. JNCI-Journal of the National Cancer Institute
- Drugs that Affect Platelet Function
- (2012) Rüdiger Scharf SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer
- (2011) Alexandre Cochet et al. BREAST CANCER RESEARCH AND TREATMENT
- Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study
- (2011) N B Leighl et al. BRITISH JOURNAL OF CANCER
- The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols
- (2011) Rachael F. Grace et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel
- (2011) Wendy Stock et al. LEUKEMIA & LYMPHOMA
- Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?
- (2010) T Dolley-Hitze et al. BRITISH JOURNAL OF CANCER
- Prevention of Torsade de Pointes in Hospital Settings
- (2010) Barbara J. Drew et al. CIRCULATION
- Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
- (2010) Mariëtte H.W. Kappers et al. HYPERTENSION
- Treatment of bevacizumab-induced hypertension by amlodipine
- (2010) Olivier Mir et al. INVESTIGATIONAL NEW DRUGS
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline-Induced Cardiomyopathy
- (2010) Daniela Cardinale et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors
- (2010) B. VAN ZAANE et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Membrane transporters in drug development
- (2010) NATURE REVIEWS DRUG DISCOVERY
- Introducing a new entity: chemotherapy-induced arrhythmia
- (2009) M. Guglin et al. EUROPACE
- Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes
- (2009) L. L. SWYSTUN et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Development and validation of a predictive model for chemotherapy-associated thrombosis
- (2008) A. A. Khorana et al. BLOOD
- Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy
- (2008) J. O. Curwen et al. CLINICAL CANCER RESEARCH
- COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs
- (2008) Timothy D Warner et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More